.Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BB05_AclidiniumBromide.AclidiniumBromide .Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BB05_AclidiniumBromide.AclidiniumBromide| name: | AclidiniumBromide |
| ATC code: | R03BB05 | route: | inhalation |
| n-compartments | 2 |
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for maintenance treatment of chronic obstructive pulmonary disease (COPD). It is administered by inhalation and approved for clinical use.
Pharmacokinetic parameters in healthy adult volunteers (both male and female), single inhaled dose.
Li, W, et al., & Garcia-Gil, E (2023). The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants. International journal of chronic obstructive pulmonary disease 18 2725–2735. DOI:10.2147/COPD.S434588 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38046981
Lal, C, & Strange, C (2015). Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert opinion on pharmacotherapy 16(3) 427–434. DOI:10.1517/14656566.2015.1000861 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25597386
Schmid, K, et al., & Jansat, JM (2010). Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clinical therapeutics 32(10) 1798–1812. DOI:10.1016/j.clinthera.2010.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21194604